Incstar obtains US approval for complement activation enzyme (CAE) assay:
This article was originally published in Clinica
Incstar (US) has been granted 510(k) clearance by the US FDA for its first-generation complement activation enzyme assay. The product was launched outside the US in the second quarter of this year. The CAE assay provides general information about the patient's immune system in certain diseases including systemic lupus erythematosus, rheumatic disorders and massive tissue injury.
You may also be interested in...
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.